Keywords
Stage II–IV
Cisplatin metronomic chemotherapy
Radiotherapy
Adverse reactions
Submitted : 2024-06-18
Accepted : 2024-07-03
Published : 2024-07-18
Abstract
Objective: To analyze the effect and adverse reaction of cisplatin metronomic chemotherapy combined with radiotherapy in the treatment of stage II–IV nasopharyngeal carcinoma. Methods: Fifty nasopharyngeal cancer patients (in stage II–IV) admitted to our hospital from January 2022 to December 2023 were selected and randomly divided into a control group and an observation group of 25 cases each. The control group was treated with cisplatin conventional chemotherapy combined with radiotherapy and the observation group was treated with cisplatin metronomic chemotherapy combined with radiotherapy. Both groups were compared in terms of recent efficacy, adverse effects, natural killer (NK) cell activity, T-cell subpopulation changes, and treatment adherence. Results: The clinical remission rate of the two groups were not significant (P > 0.05), but the incidence of adverse reactions in the observation group was lower than that in the control group, and the levels of NK cell activity, CD3, CD4, and CD4/CD8 cells in the observation group were higher than that in the control group after treatment (P < 0.05). The treatment compliance in the observation group was higher than that in the control group (P < 0.05). Conclusion: In the treatment of stage II–IV nasopharyngeal carcinoma, adopting cisplatin metronomic chemotherapy combined with radiotherapy therapy achieved better therapeutic efficacy, reduced adverse reactions, increased NK cell activity, regulated T-cell subsets, and has an overall high application value.
References
Li B, Liu J, Zhu Q, et al., 2023, Effect of Capecitabine Metronomic Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma Patients with Persistently Elevated Plasma EBV DNA after Radical Synchronous Radiotherapy. Chinese Journal of Practical Diagnosis and Therapy, 37(3): 265–268.
Xi Y, Hua P, Jiang F, et al., 2023, The Value of Delta Imaging Histology in Predicting the Efficacy of Induction Chemotherapy Combined with Simultaneous Radiotherapy in Nasopharyngeal Carcinoma. Journal of Clinical Radiology, 42(2): 216–221.
Xuan X, Lu C, Tang J, et al., 2023, Recent Efficacy of Synchronized Radiotherapy Combined with Compound Bitter Ginseng Injection for Nasopharyngeal Carcinoma and Its Effect on The Levels of Immune Factors, MIP-3-alpha, and sCD44. China Hospital Drug Evaluation and Analysis, 23(5): 524–527.
Wang C, Chen L, Qin S, 2023, Observation on the Efficacy of Teraplizumab Combined with Simultaneous Radiotherapy in The Treatment of Intermediate and Advanced Nasopharyngeal Carcinoma. Zhongnan Journal of Medical Science, 51(1): 114–116.
Zhong Q, Nie Q, Wu R, et al., 2023, Effect of Nituzumab Combined with Simultaneous Radiotherapy in The Treatment of Nasopharyngeal Carcinoma and Its Effect on Serum Tumor Markers. China Medical Innovation, 20(30): 1–5.
Wang W, Zhang Z, Li Y, et al., 2022, Correlation of ERCC1 Gene Expression in Circulating Tumor Cells with Radiotherapy Efficacy and Prognosis in Nasopharyngeal Carcinoma Patients. Chinese Journal of Gerontology, 42(13): 3166–3170.
Hu D, Chen Z, Lin Y, et al., 2023, Construction of Risk Factors and Prediction Model for Poor Prognosis of Locally Advanced Nasopharyngeal Carcinoma Treated with IMRT-Based Synchronous Radiotherapy Regimen. China Otorhinolaryngology-Head and Neck Surgery, 30(3): 148–151.
Luo H, Zhong Y, Luo Q, et al., 2022, Relationship Between the Combined Use of Proton Pump Inhibitors and The Occurrence of Acute Kidney Injury During Cisplatin-Synchronized Radiotherapy in Nasopharyngeal Carcinoma Patients. Shandong Medicine, 62(29): 28–31.
Li Ying, Wang Xiaohua, Chen Lin, 2023, Evaluation Value of DCE-MRI Combined with 3D-pCASL Parameters on The Recent Efficacy of Radiotherapy for Nasopharyngeal Carcinoma. Chinese Journal of CT and MRI, 21(12): 45–47.
Li D, Wang X, Lu X, 2022, Analysis of Factors Affecting Neutropenia Caused by Paclitaxel Combined with Platinum-Based Simultaneous Radiotherapy for Nasopharyngeal Carcinoma and Evaluation of The Rationality of Preventive Medication. China Pharmaceutical Industry, 31(24): 111–115.